A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Required: EGFR exon 19 deletion

EGFR exon 19 deletion

Required: EGFR L858R mutation in exon 21

L858R mutation in exon 21

Required: EGFR wild-type

Participants with known mutations in EGFR will be excluded (Group A,B and E).

Allowed: EGFR T790M in exon 20

which may include T790M in exon 20

Allowed: EGFR L861Q in exon 21

other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed

Allowed: EGFR G719X in exon 18

other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed

Allowed: EGFR S768I in exon 20

other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed